ILMN · Illumina, Inc.

Current Thesis

Illumina’s NovaSeq X consumables recovery now has an index-inclusion catalyst; renewed price strength and delivery against the July revenue outlook would validate it, while a weekly close below $205 would break the market thesis. S&P Dow Jones Indices announced on 2026-09-04 that Illumina will join the S&P 500 before trading opens on 2026-09-21. This replaces the previous catalyst gap with a dated event. S&P announcement.

The narrative is maturing — an inference from fresh analyst support on 2026-09-03 and 2026-09-09 alongside a weaker 2026-09-11 adjusted close of $206.45. UBS raised its target to $260 and Argus to $235, so the August claim that analyst expectations had stopped moving no longer holds. These revisions establish renewed coverage, but the small sample supports no conclusion about broad investor participation. Benzinga analyst chronology.

Bullish and bearish views on Illumina, Inc.

The model's bull view on Illumina, Inc. (ILMN), in brief: Revenue and earnings guidance increased. The bear view: Insider supply has resumed. Keith Meister’s Form 4 filed on 2026-09-04 reports a Corvex-related sale of 57,488 shares on 2026-09-02 at a weighted-average price of $213.20. This directly supersedes the earlier assertion that no sales had been reported since June; it does not… Both cases follow in full.

Bull Case

• Revenue and earnings guidance increased. Illumina’s 2026-07-30 release reported second-quarter revenue of $1.159 billion and adjusted earnings per share of $1.31. Management raised fiscal 2026 revenue guidance to $4.60–$4.64 billion and adjusted earnings guidance to $5.30–$5.40 per share. Company results.
• Clinical consumption supports the recovery. On the 2026-07-30 earnings call, management reported clinical consumables growth of 15% year over year excluding China and more than 95 NovaSeq X instrument placements during the quarter. These are operating evidence for the conversion story; continued growth remains an inference that a revenue miss or an extended conversion timeline would challenge.
• Analyst expectations moved higher. Benzinga reported UBS’s upgrade and $260 target on 2026-09-09, following Argus’s $235 target on 2026-09-03. These are attributed analyst forecasts, not company guidance or demonstrated demand. Analyst chronology.

Bear Case

• Insider supply has resumed. Keith Meister’s Form 4 filed on 2026-09-04 reports a Corvex-related sale of 57,488 shares on 2026-09-02 at a weighted-average price of $213.20. This directly supersedes the earlier assertion that no sales had been reported since June; it does not establish the seller’s motive. SEC Form 4.
• Operating conversion remains uneven. The 2026-07-30 release reported second-quarter adjusted operating margin of 22.5%, versus 23.8% a year earlier, and operating cash flow of $201 million, versus $234 million. Revenue growth therefore did not coincide with stronger performance on these measures. Company results.
• Positive headlines lack price confirmation. Despite the 2026-09-04 index announcement and 2026-09-09 UBS upgrade, the supplied adjusted series closed at $206.45 on 2026-09-11, below its 2026-08-28 close of $215.59. The endpoints establish deterioration across that interval, not the price response to either individual announcement.

Setup & Price Structure

The adjusted daily series dated 2026-09-11 shows a $206.45 close, a 52-week high of $227.69, a 9.3% distance below that high and a three-month price increase of 28.3%. The 14-day relative strength index (RSI) measured 40.6, compared with 69.2 on 2026-08-28. Momentum has weakened on that comparison; no moving-average value or trading-volume series is available to establish support from those measures.

The research boundary remains $205, the published August threshold associated with the 2026-07-30 high of $205.10. The latest supplied close remains above that boundary, but the intervening weekly closes are missing, so an uninterrupted history of holding it cannot be certified. A weekly close above the $227.69 high recorded in the 2026-09-11 series would constitute price confirmation; a weekly close below $205 first would invalidate the recovery case.

Crowding evidence is limited to the September analyst headlines, the announced index change and the dated Corvex transaction. Neither passive-fund demand nor retail participation has been quantified. The index announcement alone cannot establish the size or persistence of a new bid.

Catalyst Calendar (next 30 days)

• 2026-09-21 — S&P 500 inclusion. The change becomes effective before the market opens, according to the 2026-09-04 announcement. It supplies a dated test of whether broader index exposure coincides with price confirmation; a subsequent weekly close below $205 would reject the supportive-flow interpretation. S&P announcement.
• 2026-09-30 — Federal fiscal year end. The funding calendar remains relevant to research customers: management reported research and applied consumables down 12% year over year at the 2026-04-30 first-quarter update. No specific appropriations outcome is established here.
• ~2026-10-29, est. Third-quarter results. This remains an unconfirmed date beyond the immediate window. The operating test is the $1.14–$1.16 billion third-quarter revenue outlook attributed to management’s 2026-07-30 call. The company release calendar reviewed on 2026-09-13 did not establish a confirmed reporting date. Illumina release calendar.

What Would Change Our Mind

Loss of the July breakout structure would end the market recovery thesis: a weekly close below $205 would breach the retained research boundary associated with the 2026-07-30 high. Separately, third-quarter revenue below management’s July guide floor of $1.14 billion would invalidate the operating-delivery premise.

Evidence for successful resolution would be a weekly close above the $227.69 reference high before that price boundary fails, together with third-quarter revenue meeting management’s July outlook. The September index event cannot substitute for that operating evidence. Management’s six-to-nine-month clinical consumables conversion interval, stated on 2026-07-30, also means the second-quarter placement cohort cannot fairly be judged fully converted at the third-quarter report.

Correlation Notes

This is a single-company recovery case; the evidence supplied through 2026-09-11 contains no peer-return series supporting a genomics group-momentum claim. The 2026-09-04 S&P announcement establishes an index-membership change, not a measured correlation with the index.

Research funding is a business exposure, supported by the research and applied consumables decline reported on 2026-04-30. No return-correlation estimate with biotechnology equities, interest rates or federal funding announcements is available, so none is asserted.